investerare

"

Med en snabbt växande verksamhet i Europa och planer på en framtida lansering i USA är Sedana Medical väl positionerat för framtiden.

Vi är på god väg mot vår vision att göra inhalationssedering till en standardbehandling inom intensivvården.

Aktie

Pressmeddelanden

2026

NDA submission and improved EBITDA Second quarter 2026 January-June 2026 CEO comments NDA submission and improved EBITDA We submitted our New Drug Application...
Sedana Medical AB (publ) plans to present its interim report for the second quarter of 2026 on Friday July 17 at 13:30 CET. According to the financial...
Sedana Medical AB (publ) today announces that Mikael Haag takes office as Chief Financial Officer (CFO) and member of the Executive Management Team, effective...

Finansiella rapporter

Finansiell kalender

Senaste presentationen

No presentations found.